An observational study in Gastroesophageal Junction (GEJ) Cancer and Gastric Cancer, sponsored by The First Hospital of Jilin University. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-08-28.
Sponsored by The First Hospital of Jilin University · Observational
Gastric cancer ranks as the fifth most common malignancy worldwide and the fourth leading cause of cancer-related deaths. In China, its incidence and mortality rank third among all cancers. While the global incidence of gastric cancer is declining, proximal gastric cancer and adenocarcinoma of the esophagogastric junction (AEG) are on the rise. Due to the unique characteristics of AEG, there is no standardized treatment consensus, making the selection of an optimal surgical approach and reconstruction method crucial for improving patient outcomes.
For early-stage proximal gastric cancer and AEG, total gastrectomy (TG) and proximal gastrectomy (PG) are common surgical options. PG, increasingly favored for its function-preserving benefits, has been shown to be a safe and effective alternative to TG. While TG effectively removes lymph nodes and reduces reflux risk, it leads to permanent loss of gastric function and nutritional deficiencies. PG better preserves gastrointestinal function but is limited by the risk of reflux esophagitis, highlighting the need for improved reconstruction techniques.
Several reconstruction methods exist after PG, including esophagogastric anastomosis, jejunal interposition, double-tract reconstruction (DTR), double-flap technique (DFT), and tubular gastric anastomosis, each with varying efficacy in preventing reflux. Studies suggest that DTR reduces reflux and improves quality of life compared to esophagogastric anastomosis, while DFT, first introduced in 1998, has gained popularity for its advantages in maintaining nutrition and minimizing reflux. Additionally, tubular gastric anastomosis, which constructs a narrow gastric tube to facilitate tension-free anastomosis, has shown potential benefits for AEG patients.
Most existing studies on laparoscopic or robot-assisted reconstruction techniques for proximal gastric cancer are retrospective, lacking high-quality prospective evidence. Furthermore, comparative data on their anti-reflux efficacy and postoperative quality of life remains l
Gastric cancer is the fifth most common malignant tumor worldwide and ranks fourth in cancer-related mortality. In China, the incidence and mortality rate of gastric cancer rank third among all malignancies. While the global incidence of gastric cancer has been steadily declining, the incidence of proximal gastric cancer has been rising. Additionally, the incidence of adenocarcinoma of the esophagogastric junction (AEG) has been increasing annually, showing an upward trend worldwide. Due to its unique anatomical location and significant tumor biological heterogeneity, there is no standardized consensus on the optimal treatment for AEG. Therefore, selecting an appropriate surgical resection and reconstruction approach remains crucial for improving the prognosis of patients with proximal gastric cancer and AEG.
For early-stage proximal gastric cancer and AEG, either total gastrectomy (TG) or proximal gastrectomy (PG) can be performed. With the advancement of function-preserving surgical concepts, PG has been increasingly recognized as a viable option. The Japanese Clinical Oncology Group (JCOG1401) trial demonstrated that laparoscopic proximal gastrectomy (LPG) is a safe and effective treatment for early-stage proximal gastric cancer compared to laparoscopic total gastrectomy (LTG). However, patients undergoing TG often experience long-term postoperative quality-of-life concerns. Although TG can effectively remove lymph nodes and reduce the risk of gastroesophageal reflux, it results in the permanent loss of gastric storage, mechanical grinding, and secretory functions, as well as reduced feasibility of postoperative endoscopic examination. TG patients may also suffer from nutritional deficiencies, including vitamin B12 deficiency, iron deficiency, weight loss, anemia, diarrhea, and dumping syndrome. In contrast, PG offers advantages in preserving gastrointestinal function and nutritional status. However, its widespread adoption is limited by the risk of reflux esophagitis. Thus, selecting an optimal reconstruct
9,365 studies on the registry are indexed under Neoplasms; 2,489 are open to participants now.
This study's planned enrollment of 90 is below the median of 204 across 1,683 observational studies indexed under Neoplasms.
Browse Neoplasms studies →The First Hospital of Jilin University is the lead sponsor of 181 studies on the registry; 93 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Patients with upper gastric cancer (T1N0M0, T1N1M0, or T2N0M0 according to the AJCC 8th edition) and esophageal junction cancer (≤4cm in diameter).
Exclusion Criteria:
The DFT digestive tract reconstruction was performed in patients with gastric cancer after proximal gastrectomy
The DTR digestive tract reconstruction was performed in patients with gastric cancer after proximal gastrectomy
The TGA digestive tract reconstruction was performed in patients with gastroesophageal cancer after proximal gastrectomy
Incidence of reflux esophagitis
The proportion of patients with reflux esophagitis diagnosed by digestive endoscopy (LA classification), barium meal (barium meal) and (GerdQ scale).
Time frame: Follow-up evaluations are performed up to 2 years postoperatively.
Incidence of Postoperative complications
The total number of patients who underwent surgical treatment was used as the denominator, and the number of patients with any postoperative complication was used as the numerator to calculate the incidence percentage.
Time frame: Within 30 days after surgery
Postoperative mortality
The total number of patients who underwent surgical treatment was used as the denominator, and the number of patients who died after surgery was used as the numerator to calculate the incidence percentage.
Time frame: Within 30 days after surgery
Body weight change
Body weight will be monitored during follow-up after surgery.
Time frame: Follow-up evaluations are performed up to 2 years postoperatively.
Long-term postoperative quality of life
Quality of life was assessed by EORTC QLQ-STO22 questionnaires.
Time frame: Follow-up evaluations are performed up to 2 years postoperatively.
Long-term postoperative quality of life
Quality of life was assessed by EORTC QLQ-C30 questionnaires.
Time frame: Follow-up evaluations are performed up to 2 years postoperatively.
Postoperative albumin
Hematological examination
Time frame: Follow-up evaluations are performed up to 2 years postoperatively.
Postoperative prealbumin
Hematological examination
Time frame: Follow-up evaluations are performed up to 2 years postoperatively.
Postoperative total protein
Hematological examination
Time frame: Follow-up evaluations are performed up to 2 years postoperatively.
Postoperative hemoglobin
Hematological examination
Time frame: Follow-up evaluations are performed up to 2 years postoperatively.
Vitamin D
Hematological examination
Time frame: Follow-up evaluations are performed up to 2 years postoperatively.
Folic acid
Hematological examination
Time frame: Follow-up evaluations are performed up to 2 years postoperatively.
Vitamin B12
Hematological examination
Time frame: Follow-up evaluations are performed up to 2 years postoperatively.
Ferritin
Hematological examination
Time frame: Follow-up evaluations are performed up to 2 years postoperatively.
Sarcopenia
CT scan was performed to assess the L3 skeletal muscle index (LSMI).
Time frame: Follow-up evaluations are performed up to 2 years postoperatively.
Hp Infection
C13/14 examination by blowing or by endoscopic biopsy.
Time frame: Follow-up evaluations are performed up to 2 years postoperatively.
3-years Relapse free survival rate
Time frame: Follow-up evaluations are performed up to 3 years postoperatively.
3-years overall survival rate
Time frame: Follow-up evaluations are performed up to 3 years postoperatively.
Plan to share: Yes
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
The First Hospital of Jilin University